Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Icahn School of Medicine at Mount Sinai | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with high level of HBV DNA.
Telbivudine and Lamivudine,a preganancy category B medication,reduces HBV DNA and normalizes serum ALT in chronic hepatitis B patients with few adverse effects.Two aspects on the drug use in pregnancy will be evaluated prospectively in this study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No antiviral arm | No Intervention | provide standard of care to mothers and standard immunoprophylaxis to their infants | |
| Lamivudine | Experimental | lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants |
|
| Telbivudine | Experimental | Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telbivudine | Drug | About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun |
|
| Measure | Description | Time Frame |
|---|---|---|
| The data on its tolerability and safety in HBeAg+ pregnant woman with HBV DNA>6log10 copies/Ml during late pregnancy and infants | perinatal to 28 weeks after infant delivery | |
| Its efficacy in the reduction of HBV vertical transmission rate | perinatal to 28 weeks after infant delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Maternal DNA reduction,ALT normalization, and loss/seroconversion of HBeAg or HBsAg | perinatal to 28 weeks of postpartum |
Not provided
Inclusion Criteria:
HBeAg+CHB pregnant woman gestational age 28 weeks HBV-DNA>log10 copies/ml
Exclusion Criteria:
co-infection with hepatitis A,C,D,E or HIV evidence of hepatocellular carcinoma decompensated liver disease or significant co-morbidity concurrent treatment with immune-modulators,cytotoxic drugs,or steroids clinical signs of threatened miscarriage in early prenancy evidence of fetal deformity by ultrasound examination the biological father of the child had CHB
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hua Zhang, MD | Beijing YouAn Hospital | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D000088562 | Persistent Infection |
| D014766 | Viremia |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077712 | Telbivudine |
| D019259 | Lamivudine |
| ID | Term |
|---|---|
| D013936 | Thymidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Lamivudine | Drug | About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum |
|
| D004266 |
| DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D018805 | Sepsis |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D006571 |
| Heterocyclic Compounds |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D016047 | Zalcitabine |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D015224 | Dideoxynucleosides |